TITLE:
Systolic Pressure Efficacy and Safety Trial of Alagebrium (SPECTRA)

CONDITION:
Hypertension

INTERVENTION:
alagebrium chloride (ALT-711)

SUMMARY:

      This study comprises a 3- to 6-week hydrochlorothiazide run in phase, followed by a 12 week
      double-blind treatment phase, followed by a 2 week single-blind follow-up
      hydrochlorothiazide treatment phase. The combined total duration of patient participation is
      approximately 17-20 weeks. Four double-blind treatment groups approximately equal in size
      (98) will comprise the study population: placebo or various alagebrium dose groups (10, 50,
      or 150 mg/day).
    

DETAILED DESCRIPTION:
NONE

ELIGIBILITY:
Gender: All
Age: 45 Years to N/A
Criteria:

        Inclusion Criteria:

          -  Men or women at least 45 years of age with uncontrolled systolic hypertension
             measured by office cuff and by an ambulatory blood pressure monitoring device

          -  Willingness to be taken off any current antihypertensive treatment to be placed on
             hydrochlorothiazide in combination with study medication.

        Exclusion Criteria:

          -  Any significant history, systemic illnesses, or medical condition(s) that could lead
             to difficulty complying with the protocol or that could confound interpretation of
             the data.
      
